{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:54:37Z","timestamp":1790945677268,"version":"4.1.0"},"reference-count":139,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"unspecified","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["MCL-RI"],"award-info":[{"award-number":["MCL-RI"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"name":"pre-SPORE","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Functional Genomics Initiative","award":["Rapid Response Grant"],"award-info":[{"award-number":["Rapid Response Grant"]}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["21-ESRE-0028, ESR\/Equipex+ Onco-Pheno-Screen"],"award-info":[{"award-number":["21-ESRE-0028, ESR\/Equipex+ Onco-Pheno-Screen"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-21-RHUS-0017 Immunolife"],"award-info":[{"award-number":["ANR-21-RHUS-0017 Immunolife"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-22-CE14-0066 VIVORUSH"],"award-info":[{"award-number":["ANR-22-CE14-0066 VIVORUSH"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-CE44-0030 COPPERMAC"],"award-info":[{"award-number":["ANR-23-CE44-0030 COPPERMAC"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-R4HC-0006 Ener-LIGHT"],"award-info":[{"award-number":["ANR-23-R4HC-0006 Ener-LIGHT"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-RHUS-0010 LUCA-pi"],"award-info":[{"award-number":["ANR-23-RHUS-0010 LUCA-pi"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sandra and Edward Meyer Cancer Center","award":["Clinical Trials Innovation Grant"],"award-info":[{"award-number":["Clinical Trials Innovation Grant"]}]},{"name":"Sandra and Edward Meyer Cancer Center","award":["Collaborative Research Initiative Grant"],"award-info":[{"award-number":["Collaborative Research Initiative Grant"]}]},{"name":"NIH\/NCI","award":["CA274291"],"award-info":[{"award-number":["CA274291"]}]},{"DOI":"10.13039\/501100004795","name":"Institut Universitaire de France","doi-asserted-by":"publisher","award":["PAIR-Ob\u00e9sit\u00e9 INCa_1873"],"award-info":[{"award-number":["PAIR-Ob\u00e9sit\u00e9 INCa_1873"]}],"id":[{"id":"10.13039\/501100004795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015545","name":"Seerave Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100015545","id-type":"DOI","asserted-by":"publisher"}]},{"name":"2019 Laura Ziskin Prize in Translational Research","award":["ZP-6177"],"award-info":[{"award-number":["ZP-6177"]}]},{"name":"SIRIC Cancer Research and Personalized Medicine (CARPEM) supported by Institut National du Cancer, Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9 and INSERM","award":["SIRIC CARPEM INCa-DGOS-Inserm-ITMO Cancer_18006"],"award-info":[{"award-number":["SIRIC CARPEM INCa-DGOS-Inserm-ITMO Cancer_18006"]}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","award":["SU2C"],"award-info":[{"award-number":["SU2C"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hevolution Network on Senescence in Aging","award":["HF-E Einstein Network"],"award-info":[{"award-number":["HF-E Einstein Network"]}]},{"name":"US DoD BCRP","award":["BC180476P1"],"award-info":[{"award-number":["BC180476P1"]}]},{"name":"US DoD BCRP","award":["BC210945"],"award-info":[{"award-number":["BC210945"]}]},{"name":"US DoD BCRP","award":["W81XWH2120034"],"award-info":[{"award-number":["W81XWH2120034"]}]},{"DOI":"10.13039\/100032616","name":"STARR Cancer Consortium","doi-asserted-by":"crossref","award":["I16-0064"],"award-info":[{"award-number":["I16-0064"]}],"id":[{"id":"10.13039\/100032616","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH","award":["CA271915"],"award-info":[{"award-number":["CA271915"]}]},{"name":"Ms. Pat Pasquarello","award":["Donation"],"award-info":[{"award-number":["Donation"]}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["101095604"],"award-info":[{"award-number":["101095604"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["ICD-Cancer (ERC-2021-ADG, Grant No. 101052444)"],"award-info":[{"award-number":["ICD-Cancer (ERC-2021-ADG, Grant No. 101052444)"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["Oncobiome (Grant No. 825410)"],"award-info":[{"award-number":["Oncobiome (Grant No. 825410)"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["Prevalung EU (Grant No. 101095604)"],"award-info":[{"award-number":["Prevalung EU (Grant No. 101095604)"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ricerchiamo","award":["Donation"],"award-info":[{"award-number":["Donation"]}]},{"name":"ERA4 Health Cardinoff","award":["Ener-LIGHT"],"award-info":[{"award-number":["Ener-LIGHT"]}]},{"name":"Noxopharm","award":["Donation"],"award-info":[{"award-number":["Donation"]}]},{"DOI":"10.13039\/100018703","name":"HORIZON EUROPE European Innovation Council","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100018703","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Luke Heller TECPR2 Foundation","award":["Donation"],"award-info":[{"award-number":["Donation"]}]},{"DOI":"10.13039\/501100016037","name":"Fondation Gustave Roussy","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100016037","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sotio a.s.","award":["Donation"],"award-info":[{"award-number":["Donation"]}]},{"name":"Promontory","award":["Donation"],"award-info":[{"award-number":["Donation"]}]},{"name":"Promontory","award":["Industrial collaboration"],"award-info":[{"award-number":["Industrial collaboration"]}]},{"DOI":"10.13039\/501100006431","name":"Canc\u00e9rop\u00f4le Ile-de-France","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100006431","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Lytix Biopharma","award":["Donation"],"award-info":[{"award-number":["Donation"]}]},{"name":"Lytix Biopharma","award":["Industrial collaboration"],"award-info":[{"award-number":["Industrial collaboration"]}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["N\/A to GK"],"award-info":[{"award-number":["N\/A to GK"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["N\/A to OKE"],"award-info":[{"award-number":["N\/A to OKE"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["(\u00e9quipe labellis\u00e9e)"],"award-info":[{"award-number":["(\u00e9quipe labellis\u00e9e)"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Onxeo","award":["Donation"],"award-info":[{"award-number":["Donation"]}]},{"name":"Onxeo","award":["Industrial collaboration"],"award-info":[{"award-number":["Industrial collaboration"]}]},{"DOI":"10.13039\/100007391","name":"Association pour la Recherche sur le Cancer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100007391","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dept. of Radiation Oncology at Weill Cornell Medicine","award":["Startup funds"],"award-info":[{"award-number":["Startup funds"]}]},{"DOI":"10.13039\/100007322","name":"Fox Chase Cancer Center","doi-asserted-by":"publisher","award":["Startup Funds"],"award-info":[{"award-number":["Startup Funds"]}],"id":[{"id":"10.13039\/100007322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IDEX Universit\u00e9 de Paris Cit\u00e9","award":["ANR-18-IDEX-0001"],"award-info":[{"award-number":["ANR-18-IDEX-0001"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,1,20]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>Oncolytic peptides (OLPs) constitute an emerging class of immunotherapeutics that combine direct cancer cell lysis with immune activation. Indeed, OLPs induce rapid immunogenic cell death by disrupting intracellular membranes, which culminates with the abundant release of malignant cell contents including immunostimulatory danger-associated molecular patterns. This results in the engagement of innate immune sensors that potently activate dendritic cells, leading to the cross-priming of tumor-specific T lymphocytes that mediate systemic anticancer immunity. Through such a dual mechanism, OLPs can remodel the tumor microenvironment and overcome resistance to therapy as promoted by intratumoral heterogeneity, hence representing optimal combinatorial partners for immune checkpoint inhibitors. Some OLPs have also shown remarkable clinical efficacy. For instance, LTX-315 (studied as VP-315 in basal cell carcinoma (BCC)) has recently been shown to enable complete and durable responses in patients with BCC, and emerging evidence points to a significant activity of LTX-315 in immunologically cold tumors. Here, we summarize recent mechanistic, preclinical, and clinical advances in OLP development, underscoring their potential as a versatile and powerful modality of cancer immunotherapy.<\/jats:p>","DOI":"10.1136\/jitc-2025-013337","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:56:10Z","timestamp":1770828970000},"page":"e013337","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Immunobiological mechanisms of action of oncolytic peptides"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct01058616","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01986426","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05188729","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04796194","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06651151","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04260529","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01485848","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02225366","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01986426","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-9558","authenticated-orcid":false,"given":"Oliver","family":"Kepp","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Sorbonne Universit\u00e9, Inserm, Centre de Recherche des Cordeliers, Equipe labellis\u00e9e par la Ligue contre le cancer, Institut Universitaire de France, Paris, France"},{"name":"Universit\u00e9 Paris-Saclay, INSERM US23\/CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolian","family":"Deng","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Sorbonne Universit\u00e9, Inserm, Centre de Recherche des Cordeliers, Equipe labellis\u00e9e par la Ligue contre le cancer, Institut Universitaire de France, Paris, France"},{"name":"Universit\u00e9 Paris-Saclay, INSERM US23\/CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enfu","family":"Xue","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Sorbonne Universit\u00e9, Inserm, Centre de Recherche des Cordeliers, Equipe labellis\u00e9e par la Ligue contre le cancer, Institut Universitaire de France, Paris, France"},{"name":"Universit\u00e9 Paris-Saclay, INSERM US23\/CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baldur","family":"Sveinbj\u00f8rnsson","sequence":"additional","affiliation":[{"name":"Lytix Biopharma, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Rekdal","sequence":"additional","affiliation":[{"name":"Lytix Biopharma, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-8500","authenticated-orcid":false,"given":"Lorenzo","family":"Galluzzi","sequence":"additional","affiliation":[{"name":"Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-4405","authenticated-orcid":false,"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Sorbonne Universit\u00e9, Inserm, Centre de Recherche des Cordeliers, Equipe labellis\u00e9e par la Ligue contre le cancer, Institut Universitaire de France, Paris, France"},{"name":"Universit\u00e9 Paris-Saclay, INSERM US23\/CNRS UAR 3655, Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France"},{"name":"Institut du Cancer Paris CARPEM, Department of Biology, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, Paris, France, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"2026021108560060000_14.2.e013337.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1249481"},{"key":"2026021108560060000_14.2.e013337.2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80011"},{"key":"2026021108560060000_14.2.e013337.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0337-2"},{"key":"2026021108560060000_14.2.e013337.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.12.013"},{"key":"2026021108560060000_14.2.e013337.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01233-9"},{"key":"2026021108560060000_14.2.e013337.6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.830292","article-title":"Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment","volume":"13","author":"Andrea","year":"2022","journal-title":"Front Immunol"},{"key":"2026021108560060000_14.2.e013337.7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002723","article-title":"Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead","volume":"9","author":"Kirtane","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026021108560060000_14.2.e013337.8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41392-025-02340-6","article-title":"Epigenetic regulation of cancer stemness","volume":"10","author":"Galassi","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026021108560060000_14.2.e013337.9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0296"},{"key":"2026021108560060000_14.2.e013337.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.09.010"},{"key":"2026021108560060000_14.2.e013337.11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.799455","article-title":"Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade","volume":"12","author":"Genova","year":"2021","journal-title":"Front Immunol"},{"key":"2026021108560060000_14.2.e013337.12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026021108560060000_14.2.e013337.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.09.001"},{"key":"2026021108560060000_14.2.e013337.14","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3245"},{"key":"2026021108560060000_14.2.e013337.15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7807","article-title":"The hallmarks of successful anticancer immunotherapy","volume":"10","author":"Galluzzi","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026021108560060000_14.2.e013337.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00920-9"},{"key":"2026021108560060000_14.2.e013337.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"2026021108560060000_14.2.e013337.18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.trecan.2020.12.012","article-title":"Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides","volume":"7","author":"Vitale","year":"2021","journal-title":"Trends Cancer"},{"key":"2026021108560060000_14.2.e013337.19","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.117"},{"key":"2026021108560060000_14.2.e013337.20","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.41"},{"key":"2026021108560060000_14.2.e013337.21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2015.10","article-title":"One of these things is not like the others","volume":"16","author":"Seton-Rogers","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2026021108560060000_14.2.e013337.22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.chembiol.2016.12.009","article-title":"Glycan Alteration Imparts Cellular Resistance to a Membrane-Lytic Anticancer Peptide","volume":"24","author":"Ishikawa","year":"2017","journal-title":"Cell Chem Biol"},{"key":"2026021108560060000_14.2.e013337.23","doi-asserted-by":"crossref","first-page":"10558","DOI":"10.3390\/ijms231810558","article-title":"Biophysical Characterization of LTX-315 Anticancer Peptide Interactions with Model Membrane Platforms: Effect of Membrane Surface Charge","volume":"23","author":"Koo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026021108560060000_14.2.e013337.24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.15407\/exp-oncology.2024.01.003","article-title":"ANTICANCER IMMUNOGENIC POTENTIAL OF ONCOLYTIC PEPTIDES: RECENT ADVANCES AND NEW PROSPECTS","volume":"46","author":"Khranovska","year":"2024","journal-title":"Exp oncol"},{"key":"2026021108560060000_14.2.e013337.25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5308"},{"key":"2026021108560060000_14.2.e013337.26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41571-021-00490-4","article-title":"Advancing oncolytic virus therapy by understanding the biology","volume":"18","author":"Kaufman","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026021108560060000_14.2.e013337.27","doi-asserted-by":"publisher","DOI":"10.1038\/nri1180"},{"key":"2026021108560060000_14.2.e013337.28","doi-asserted-by":"publisher","DOI":"10.1038\/ni1206"},{"key":"2026021108560060000_14.2.e013337.29","doi-asserted-by":"publisher","DOI":"10.1038\/nri1860"},{"key":"2026021108560060000_14.2.e013337.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00602-4"},{"key":"2026021108560060000_14.2.e013337.31","doi-asserted-by":"crossref","first-page":"1548603","DOI":"10.3389\/fmed.2025.1548603","article-title":"Cationic antimicrobial peptides: potential templates for anticancer agents","volume":"12","author":"Varela-Quiti\u00e1n","year":"2025","journal-title":"Front Med"},{"key":"2026021108560060000_14.2.e013337.32","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c05288"},{"key":"2026021108560060000_14.2.e013337.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0058-8"},{"key":"2026021108560060000_14.2.e013337.34","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.13.2.97"},{"key":"2026021108560060000_14.2.e013337.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106674","article-title":"Design, synthesis and anticancer evaluation of novel oncolytic peptide-chlorambucil conjugates","volume":"138","author":"Yin","year":"2023","journal-title":"Bioorg Chem"},{"key":"2026021108560060000_14.2.e013337.36","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.47","article-title":"The oncolytic peptide LTX-315 triggers immunogenic cell death","volume":"7","author":"Zhou","year":"2016","journal-title":"Cell Death Dis"},{"key":"2026021108560060000_14.2.e013337.37","doi-asserted-by":"crossref","DOI":"10.4161\/onci.29181","article-title":"LTX-315 (Oncopore): A short synthetic anticancer peptide and novel immunotherapeutic agent","volume":"3","author":"Camilio","year":"2014","journal-title":"Oncoimmunology"},{"key":"2026021108560060000_14.2.e013337.38","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.4155\/fmc-2017-0088","article-title":"LTX-315: A First-In-Class Oncolytic Peptide that Reprograms the Tumor Microenvironment","volume":"9","author":"Sveinbj\u2298rnsson","year":"2017","journal-title":"Future Med Chem"},{"key":"2026021108560060000_14.2.e013337.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01102-9"},{"key":"2026021108560060000_14.2.e013337.40","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.25251\/skin.10.supp.565","article-title":"Calculated Objective Response Rate (ORR) of 97% from Post-Hoc Analysis of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational therapy for Basal Cell Carcinoma (BCC)","volume":"9","author":"Kantor","year":"2025","journal-title":"J of Skin"},{"key":"2026021108560060000_14.2.e013337.41","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/cdd.2016.86","article-title":"The oncolytic compound LTX-401 targets the Golgi apparatus","volume":"23","author":"Zhou","year":"2016","journal-title":"Cell Death Differ"},{"key":"2026021108560060000_14.2.e013337.42","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1594555","article-title":"Tumor lysis with LTX-401 creates anticancer immunity","volume":"8","author":"Xie","year":"2019","journal-title":"Oncoimmunology"},{"key":"2026021108560060000_14.2.e013337.43","doi-asserted-by":"crossref","first-page":"1028600","DOI":"10.3389\/fonc.2022.1028600","article-title":"Hybrid peptide NTP-217 triggers ROS-mediated rapid necrosis in liver cancer cells by induction of mitochondrial leakage","volume":"12","author":"Yin","year":"2022","journal-title":"Front Oncol"},{"key":"2026021108560060000_14.2.e013337.44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201220","article-title":"The anticancer peptide RT53 induces immunogenic cell death","volume":"13","author":"Pasquereau-Kotula","year":"2018","journal-title":"PLoS One"},{"key":"2026021108560060000_14.2.e013337.45","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-86239-6","article-title":"Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer","volume":"11","author":"Fleten","year":"2021","journal-title":"Sci Rep"},{"key":"2026021108560060000_14.2.e013337.46","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12964-024-01731-6","article-title":"Hainanenin-1, an oncolytic peptide, triggers immunogenic cell death via STING activation in triple-negative breast cancer","volume":"22","author":"Li","year":"2024","journal-title":"Cell Commun Signal"},{"key":"2026021108560060000_14.2.e013337.47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12010-007-8024-z","article-title":"PCR-based gene synthesis, molecular cloning, high level expression, purification, and characterization of novel antimicrobial peptide, brevinin-2R, in Escherichia coli","volume":"149","author":"Mehrnejad","year":"2008","journal-title":"Appl Biochem Biotechnol"},{"key":"2026021108560060000_14.2.e013337.48","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.18632\/oncotarget.2959","article-title":"The antimicrobial peptide pardaxin exerts potent anti-tumor activity against canine perianal gland adenoma","volume":"6","author":"Pan","year":"2015","journal-title":"Oncotarget"},{"key":"2026021108560060000_14.2.e013337.49","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/md18080417","article-title":"Antimicrobial Peptide TP4 Targets Mitochondrial Adenine Nucleotide Translocator 2","volume":"18","author":"Su","year":"2020","journal-title":"Mar Drugs"},{"key":"2026021108560060000_14.2.e013337.50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-401364"},{"key":"2026021108560060000_14.2.e013337.51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0484"},{"key":"2026021108560060000_14.2.e013337.52","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10392","article-title":"Shaping the \u201chot\u201d immunogenic tumor microenvironment by nanoparticles co-delivering oncolytic peptide and TGF-beta1 siRNA for boosting checkpoint blockade therapy","volume":"8","author":"Phung","year":"2023","journal-title":"Bioeng Transl Med"},{"key":"2026021108560060000_14.2.e013337.53","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.7150\/thno.71129","article-title":"Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer","volume":"12","author":"Lu","year":"2022","journal-title":"Theranostics"},{"key":"2026021108560060000_14.2.e013337.54","doi-asserted-by":"publisher","DOI":"10.1038\/299371a0"},{"key":"2026021108560060000_14.2.e013337.55","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3011.2002.21008.x"},{"key":"2026021108560060000_14.2.e013337.56","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10167","article-title":"The wasp venom antimicrobial peptide polybia-CP and its synthetic derivatives display antiplasmodial and anticancer properties","volume":"5","author":"Torres","year":"2020","journal-title":"Bioeng Transl Med"},{"key":"2026021108560060000_14.2.e013337.57","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3389\/fphar.2018.01297","article-title":"N-myristoylation of Antimicrobial Peptide CM4 Enhances Its Anticancer Activity by Interacting With Cell Membrane and Targeting Mitochondria in Breast Cancer Cells","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026021108560060000_14.2.e013337.58","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.279281"},{"key":"2026021108560060000_14.2.e013337.59","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1021\/bi300836r","article-title":"Anticancer peptide SVS-1: efficacy precedes membrane neutralization","volume":"51","author":"Gaspar","year":"2012","journal-title":"Biochemistry"},{"key":"2026021108560060000_14.2.e013337.60","doi-asserted-by":"crossref","first-page":"117760","DOI":"10.1016\/j.bmc.2024.117760","article-title":"Synthesis and structural optimization of oncolytic peptide LTX-315","volume":"107","author":"Song","year":"2024","journal-title":"Bioorg Med Chem"},{"key":"2026021108560060000_14.2.e013337.61","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1021\/acs.jmedchem.5b02025","article-title":"Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide","volume":"59","author":"Haug","year":"2016","journal-title":"J Med Chem"},{"key":"2026021108560060000_14.2.e013337.62","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010581","article-title":"Understanding the Biophysical Interaction of LTX-315 with Tumoral Model Membranes","volume":"24","author":"Klaiss-Luna","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026021108560060000_14.2.e013337.63","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jconrel.2021.06.032","article-title":"Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma","volume":"336","author":"Xia","year":"2021","journal-title":"J Control Release"},{"key":"2026021108560060000_14.2.e013337.64","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1021\/acs.molpharmaceut.4c01144","article-title":"Efficient Delivery of Oncolytic Peptide LTX-315 by ZIF-8: pH-Responsive Release, Improved Stability, and Reduced Hemolysis","volume":"22","author":"Chen","year":"2025","journal-title":"Mol Pharm"},{"key":"2026021108560060000_14.2.e013337.65","doi-asserted-by":"crossref","DOI":"10.1002\/psc.3482","article-title":"Development of membrane-active peptide therapeutics in oncology","volume":"29","author":"Chen","year":"2023","journal-title":"J Pept Sci"},{"key":"2026021108560060000_14.2.e013337.66","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1080\/15384101.2016.1160609","article-title":"LTX-315, CAPtivating immunity with necrosis","volume":"15","author":"Sistigu","year":"2016","journal-title":"Cell Cycle"},{"key":"2026021108560060000_14.2.e013337.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.049"},{"key":"2026021108560060000_14.2.e013337.68","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486"},{"key":"2026021108560060000_14.2.e013337.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.11.024"},{"key":"2026021108560060000_14.2.e013337.70","doi-asserted-by":"publisher","DOI":"10.1126\/science.1071059"},{"key":"2026021108560060000_14.2.e013337.71","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12574"},{"key":"2026021108560060000_14.2.e013337.72","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.222"},{"key":"2026021108560060000_14.2.e013337.73","doi-asserted-by":"crossref","first-page":"2511031","DOI":"10.1080\/02656736.2025.2511031","article-title":"Radiofrequency hyperthermia enhances the antitumor efficacy of oncolytic peptide LTX-315 in liver cancer cells by activating of cGAS-STING pathway","volume":"42","author":"Zhou","year":"2025","journal-title":"Int J Hyperthermia"},{"key":"2026021108560060000_14.2.e013337.74","doi-asserted-by":"crossref","first-page":"1332922","DOI":"10.3389\/fimmu.2024.1332922","article-title":"LTX-315 triggers anticancer immunity by inducing MyD88-dependent maturation of dendritic cells","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"2026021108560060000_14.2.e013337.75","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00760-x"},{"key":"2026021108560060000_14.2.e013337.76","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-022-00589-6"},{"key":"2026021108560060000_14.2.e013337.77","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1962592","article-title":"LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells","volume":"10","author":"Yamazaki","year":"2021","journal-title":"Oncoimmunology"},{"key":"2026021108560060000_14.2.e013337.78","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005065","article-title":"Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity","volume":"10","author":"Tang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026021108560060000_14.2.e013337.79","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004129","article-title":"Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis","volume":"10","author":"Tang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026021108560060000_14.2.e013337.80","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4574"},{"key":"2026021108560060000_14.2.e013337.81","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/jimmun\/vkaf139","article-title":"Isolation of mitochondrial mutation-specific T cell receptors","volume":"214","author":"Kirkpatrick","year":"2025","journal-title":"J Immunol"},{"key":"2026021108560060000_14.2.e013337.82","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0557-x"},{"key":"2026021108560060000_14.2.e013337.83","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3435"},{"key":"2026021108560060000_14.2.e013337.84","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-1127-3","article-title":"Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals","volume":"9","author":"Zhou","year":"2018","journal-title":"Cell Death Dis"},{"key":"2026021108560060000_14.2.e013337.85","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405"},{"key":"2026021108560060000_14.2.e013337.86","doi-asserted-by":"publisher","DOI":"10.1038\/nri2780"},{"key":"2026021108560060000_14.2.e013337.87","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00588-9"},{"key":"2026021108560060000_14.2.e013337.88","doi-asserted-by":"crossref","first-page":"348","DOI":"10.15698\/cst2019.11.204","article-title":"LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects","volume":"3","author":"Liao","year":"2019","journal-title":"Cell Stress"},{"key":"2026021108560060000_14.2.e013337.89","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41580-025-00869-6","article-title":"Regulation of inflammatory processes by caspases","volume":"26","author":"Beltr\u00e1n-Visiedo","year":"2025","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026021108560060000_14.2.e013337.90","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00262-014-1540-0","article-title":"Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315","volume":"63","author":"Camilio","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"2026021108560060000_14.2.e013337.91","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1338236","article-title":"Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model","volume":"6","author":"Nestvold","year":"2017","journal-title":"Oncoimmunology"},{"key":"2026021108560060000_14.2.e013337.92","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2290900","article-title":"LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma","volume":"13","author":"Nielsen","year":"2024","journal-title":"Oncoimmunology"},{"key":"2026021108560060000_14.2.e013337.93","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01040-6"},{"key":"2026021108560060000_14.2.e013337.94","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00546-2"},{"key":"2026021108560060000_14.2.e013337.95","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-1105"},{"key":"2026021108560060000_14.2.e013337.96","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41568-025-00832-9","article-title":"Regulatory T cells in the tumour microenvironment","volume":"25","author":"Imianowski","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"2026021108560060000_14.2.e013337.97","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01126-7"},{"key":"2026021108560060000_14.2.e013337.98","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41420-024-02180-3","article-title":"Biological function of sialic acid and sialylation in human health and disease","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Death Discov"},{"key":"2026021108560060000_14.2.e013337.99","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090206"},{"key":"2026021108560060000_14.2.e013337.100","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2011.07.026"},{"key":"2026021108560060000_14.2.e013337.101","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/cdd.2016.35","article-title":"The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade","volume":"23","author":"Yamazaki","year":"2016","journal-title":"Cell Death Differ"},{"key":"2026021108560060000_14.2.e013337.102","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13256-019-2088-6","article-title":"Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report","volume":"13","author":"Jebsen","year":"2019","journal-title":"J Med Case Rep"},{"key":"2026021108560060000_14.2.e013337.103","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.omto.2019.05.002","article-title":"The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma","volume":"14","author":"Mauseth","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"2026021108560060000_14.2.e013337.104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148980","article-title":"The Cytolytic Amphipathic \u03b2(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma","volume":"11","author":"Eike","year":"2016","journal-title":"PLoS ONE"},{"key":"2026021108560060000_14.2.e013337.105","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-018-1092-x","article-title":"Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model","volume":"21","author":"Camilio","year":"2019","journal-title":"Breast Cancer Res"},{"key":"2026021108560060000_14.2.e013337.106","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246093","article-title":"Interventional Oncolytic Immunotherapy with LTX-315 for Residual Tumor after Incomplete Radiofrequency Ablation of Liver Cancer","volume":"14","author":"Zhou","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026021108560060000_14.2.e013337.107","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41419-025-07622-z","article-title":"Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma","volume":"16","author":"Sun","year":"2025","journal-title":"Cell Death Dis"},{"key":"2026021108560060000_14.2.e013337.108","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-022-00699-x","article-title":"Targeting drugs to tumours using cell membrane-coated nanoparticles","volume":"20","author":"Fang","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2026021108560060000_14.2.e013337.109","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202503561","article-title":"Long-Acting In Situ Cancer Vaccines by Oncolytic STING-Activating Microgels","volume":"21","author":"Tan","year":"2025","journal-title":"Small"},{"key":"2026021108560060000_14.2.e013337.110","doi-asserted-by":"crossref","first-page":"S636","DOI":"10.1016\/j.annonc.2023.09.2190","article-title":"1051P Intratumoral injection of LTX-315 in combination with pembrolizumab in patients with advanced melanoma refractory to prior PD-1\/PD-L1 therapy: Interim results from the ATLAS-IT-05 trial","volume":"34","author":"Dalle","year":"2023","journal-title":"Ann Oncol"},{"key":"2026021108560060000_14.2.e013337.111","doi-asserted-by":"crossref","first-page":"S758","DOI":"10.1016\/j.annonc.2022.07.604","article-title":"476P First-in-human, dose-escalation phase I trial of intratumoral (IT) CyPep-1 in patients (pts) with advanced solid tumors","volume":"33","author":"Eskens","year":"2022","journal-title":"Ann Oncol"},{"key":"2026021108560060000_14.2.e013337.112","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-019-0272-7","article-title":"Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies","volume":"17","author":"Kepp","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2026021108560060000_14.2.e013337.113","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25122850"},{"key":"2026021108560060000_14.2.e013337.114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.11.014"},{"key":"2026021108560060000_14.2.e013337.115","doi-asserted-by":"publisher","DOI":"10.1038\/nrm4073"},{"key":"2026021108560060000_14.2.e013337.116","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-018-0042-2"},{"key":"2026021108560060000_14.2.e013337.117","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-023-00585-z"},{"key":"2026021108560060000_14.2.e013337.118","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3608"},{"key":"2026021108560060000_14.2.e013337.119","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.71"},{"key":"2026021108560060000_14.2.e013337.120","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22853","article-title":"Polypeptide LTX\u2010315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin\u20101\/PI3K\/mTOR signaling pathway","volume":"35","author":"Ma","year":"2021","journal-title":"J Biochem & Molecular Tox"},{"key":"2026021108560060000_14.2.e013337.121","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0235-4"},{"key":"2026021108560060000_14.2.e013337.122","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00431-4"},{"key":"2026021108560060000_14.2.e013337.123","doi-asserted-by":"publisher","DOI":"10.1038\/S41568-020-0285-7"},{"key":"2026021108560060000_14.2.e013337.124","doi-asserted-by":"crossref","first-page":"178152","DOI":"10.1016\/j.ejphar.2025.178152","article-title":"Spotlight on membrane fluidity of normal and cancer cells: Implications for cancer diagnosis and treatment","volume":"1006","author":"Canaparo","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"2026021108560060000_14.2.e013337.125","doi-asserted-by":"publisher","DOI":"10.1007\/s10863-020-09846-4"},{"key":"2026021108560060000_14.2.e013337.126","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.16"},{"key":"2026021108560060000_14.2.e013337.127","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41568-025-00847-2","article-title":"Advancing engineering design strategies for targeted cancer nanomedicine","volume":"25","author":"Gomerdinger","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"2026021108560060000_14.2.e013337.128","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00129.x"},{"key":"2026021108560060000_14.2.e013337.129","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.22.6.1926-1935.2002"},{"key":"2026021108560060000_14.2.e013337.130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176971","article-title":"A novel multifunctional peptide oligomer of bacitracin with possible bioindustrial and therapeutic applications from a Korean food-source Bacillus strain","volume":"12","author":"Choi","year":"2017","journal-title":"PLoS ONE"},{"key":"2026021108560060000_14.2.e013337.131","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2008.10.007"},{"key":"2026021108560060000_14.2.e013337.132","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.peptides.2012.01.014","article-title":"Hainanenins: A novel family of antimicrobial peptides with strong activity from Hainan cascade-frog, Amolops hainanensis","volume":"33","author":"Zhang","year":"2012","journal-title":"Peptides"},{"key":"2026021108560060000_14.2.e013337.133","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3021"},{"key":"2026021108560060000_14.2.e013337.134","doi-asserted-by":"crossref","first-page":"10151","DOI":"10.1016\/j.biomaterials.2013.09.041","article-title":"A cancer vaccine based on the marine antimicrobial peptide pardaxin (GE33) for control of bladder-associated tumors","volume":"34","author":"Huang","year":"2013","journal-title":"Biomaterials"},{"key":"2026021108560060000_14.2.e013337.135","doi-asserted-by":"publisher","DOI":"10.1038\/srep20823"},{"key":"2026021108560060000_14.2.e013337.136","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211187","article-title":"Interaction of two antitumor peptides with membrane lipids \u2013 Influence of phosphatidylserine and cholesterol on specificity for melanoma cells","volume":"14","author":"Wodlej","year":"2019","journal-title":"PLoS ONE"},{"key":"2026021108560060000_14.2.e013337.137","doi-asserted-by":"publisher","DOI":"10.1007\/s10534-014-9749-0"},{"key":"2026021108560060000_14.2.e013337.138","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1728871","article-title":"Prophylactic and therapeutic antileukemic effects induced by the AAC-11-derived Peptide RT53","volume":"9","author":"Habault","year":"2020","journal-title":"Oncoimmunology"},{"key":"2026021108560060000_14.2.e013337.139","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0302"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:56:24Z","timestamp":1770828984000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":139,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,11]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/jitc-2025-013337"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013337","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}